Reassurance on infection risk with checkpoint inhibitors

Rates of infection appear similar in patients with solid tumours before and after they receive immune checkpoint inhibitor (ICI) therapy. A retrospective study from the Canberra Hospital assessed infection rates in 327 patients who commenced ICIs between 2012 and 2019. Patients were mainly being treated for metastatic disease in melanoma (47%) and NSCLC (36%) and ...

Already a member?

Login to keep reading.

© 2022 the limbic